Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Pfizer Inc.

Virtual Tumor Board®: The Importance of Molecular Testing in Lung Cancer to Optimize Precision Care

Release Date: November 09, 2020
Expiration Date: November 09, 2021

Activity Overview

The rapid development of targeted therapies, whether available in the clinic or in clinical trials, has put increased emphasis and urgency on the critical need for implementing genomic testing into diagnostic and treatment strategies for patients with non–small cell lung cancer (NSCLC). Identifying mutations in oncogenic drivers such as EGFR, ALK, ROS1, and BRAF, as well as other targets such as RET, NTRK, and MET exon 14 mutations may play a key role in treatment decision-making. In addition, there is ongoing research into therapies for patients with EGFR exon 20 mutations, KRAS mutations, and HER2 mutations. Rapid and reliable large-scale testing using next-generation sequencing and perhaps liquid biopsy is essential in the appropriate management of this disease.

This on-demand symposium is designed to aid physicians in assessing the wealth of emerging data in treating NSCLC, choosing appropriate treatment based upon patient and tumor characteristics, and applying novel management strategies to their practices to improve the care of patients. This program focuses on testing strategies and application of evolving clinical trial data for more common mutational drivers in a practical, “real-world” tumor board format that physicians are accustomed to in their clinical practices.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, pathologists, and fellows involved in the treatment and management of patients with NSCLC. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of NSCLC may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the role of tissue- and liquid-based genomic testing for the identification of actionable molecular alterations in NSCLC
  • Evaluate best practices in tissue stewardship and conservation to facilitate comprehensive molecular testing in NSCLC
  • Assess efficacy and safety data for novel targeted therapies based on predictive molecular biomarkers
  • Incorporate emerging evidence regarding diagnostic testing and targeted therapies into challenging clinical scenarios in NSCLC

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Suresh S. Ramalingam, MD, FACP, FASCO
Suresh S. Ramalingam, MD, FACP, FASCO
Roberto C. Goizueta Distinguished Chair for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Emory University
Atlanta, GA

Disclosures: Grant Research Support: Tesaro, Merck & Co., AstraZeneca, Advaxis, Bristol Myers Squibb, Amgen; Consultant: Amgen, AbbVie, Bristol Myers Squibb, Genentech, Merck & Co., AstraZeneca, Takeda.

Sanja Dacic, MD, PhD
Sanja Dacic, MD, PhD
Professor of Pathology
University of Pittsburgh Medical Center
Department of Pathology
Pittsburgh, PA

Disclosures: Consultant: AstraZeneca.

Shirish M. Gadgeel, MD
Shirish M. Gadgeel, MD
Professor, Department of Internal Medicine
Division Head, Division of Hematology and Oncology
Henry Ford Health System
Detroit, MI

Disclosures: Grant Research Support: Merck & Co.; Consultant: Genentech/Roche, Bristol Myers Squibb, Loxo Oncology, AstraZeneca, Novartis Pharmaceuticals, Daichii Sankyo.

Zofia Piotrowska, MD
Zofia Piotrowska, MD
Assistant Professor of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: AstraZeneca, Novartis Pharmaceuticals, Spectrum Pharmaceuticals, Takeda, Tesaro; Consultant: AstraZeneca, ImmunoGen, Spectrum Pharmaceuticals, Guardant Health, Takeda/Ariad Pharmaceuticals, Novartis Pharmaceuticals, Genentech, Eli Lilly & Company, Incyte, Medtronic.

Ignacio I. Wistuba, MD
Ignacio I. Wistuba, MD
Professor and Chair, Department of Translational Molecular Pathology
Anderson Clinical Faculty Chair for Cancer Treatment and Research
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: 4D Pharma, Adaptive Biotechnologies, Adaptimmune Therapeutics, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, DEPArray™ System, EMD Serono, Genentech, HTG Molecular Diagnostics, Johnson & Johnson, Karus Therapeutics, MedImmune, Merck & Co., Novartis Pharmaceuticals, Pfizer, Takeda; Consultant: AstraZeneca, Asuragen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, HTG Molecular Diagnostics, KSD Technologies, Merck & Co., Pfizer, Roche; Speakers Bureau: Guardant Health, Merck Sharp & Dohme Corp., Pfizer, Roche.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By